FDA: PPIs and Clostridium Difficile

Published Online: Friday, July 20, 2012
Follow Pharmacy_Times:
In this podcast, Steve Jackson, a pharmacist in the FDA’s division of drug information, warns that use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea.
 
To listen to the podcast, click here.
Related Articles
A recent review of inappropriate prescribing among hospitalized older adults revealed that proton pump inhibitors follow only opiates and benzodiazepines as the most frequently misprescribed medications.
A new Mayo Clinic study published in Microbiome shows that patients with acid reflux who regularly receive proton pump inhibitors have less diverse gut bacteria, which heightens their risk for bone fractures, vitamin deficiencies, and infections such as Clostridium difficile and pneumonia.
Patients on 20-mg maintenance doses of esomeprazole reported no more than mild symptom severity.
As a result of confusing sensations of breathlessness with asthma symptoms, overweight and obese children tend to report poorer asthma control and overuse rescue medications.
Latest Issues
$auto_registration$